Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

IntroductionThe HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intracellular signal transduction pathways resulting in receptor interaction and cross-activation. The most famous family member is HER2, which is a target in Herceptin™ therapy in metastatic status and also in adjuvant therapy of breast cancer in the event of dysregulation as a result of gene amplification and resulting protein overexpression. The HER2-related HER receptors have been shown to interact directly with HER2 receptors and thereby mutually affect their activity and subsequent malignant growth potential. However, the clinical outcome with regard to total HER receptor state remains largely unknown.MethodsWe investigated HER1–HER4, at both the DNA and the protein level, using fluorescence in situ hybridisation (FISH) probes targeted to all four receptor loci and also immunohistochemistry in tissue microarrays derived from 278 breast cancer patients.ResultsWe retrospectively found HER3 gene amplification with a univariate negative impact on disease-free survival (hazard ratio 2.35, 95% confidence interval 1.08 to 5.11, p = 0.031), whereas HER4 amplification showed a positive trend in overall and disease-free survival. Protein expression revealed no additional information.ConclusionOverall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information. The continuation of explorative and prospective studies on all HER receptors will be required for an evaluation of their potential use for specific therapeutic targeting with respect to individualised therapy.

[1]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[2]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[3]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[4]  Y. Yarden,et al.  Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. , 1996, The American journal of pathology.

[5]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[6]  A. Podhajska,et al.  Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. , 1998, Gene.

[7]  Suo,et al.  Type 1 protein tyrosine kinases in benign and malignant breast lesions , 1998, Histopathology.

[8]  John O'Quigley,et al.  An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .

[9]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[10]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Neve,et al.  Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.

[12]  D. Slamon.  Herceptin: increasing survival in metastatic breast cancer. , 2000, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[13]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[14]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[15]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[16]  M. Campiglio,et al.  HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[18]  L. Caskey,et al.  HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells , 2001, Molecular and Cellular Biology.

[19]  J. Nesland,et al.  EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.

[20]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[21]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[22]  S. Tsutsui,et al.  Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. , 2003, Surgery.

[23]  D. Stern,et al.  ErbBs in mammary development. , 2003, Experimental cell research.

[24]  G. Hortobagyi,et al.  Growth factor receptors in breast cancer: potential for therapeutic intervention. , 2003, The oncologist.

[25]  J. R. Reeves,et al.  Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.

[26]  E. Kubista,et al.  Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. , 2004, Breast cancer research and treatment.

[27]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[28]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  I. Bièche,et al.  Prognostic value of ERBB family mRNA expression in breast carcinomas , 2003, International journal of cancer.

[30]  F. Esteva.  Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. , 2004, The oncologist.

[31]  Irina Klaman,et al.  Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. , 2004, International journal of oncology.

[32]  John M.S. Bartlett,et al.  Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? , 2005, Clinical Cancer Research.

[33]  R. Knuechel,et al.  Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin‐embedded breast cancer , 2005, The Journal of pathology.

[34]  T. Stephenson,et al.  HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques , 2005, Journal of Clinical Pathology.

[35]  N. Bundred,et al.  Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In situ of the Breast , 2005, Clinical Cancer Research.

[36]  A. Giordano,et al.  Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. , 2005, Endocrine-related cancer.

[37]  János Szöllosi,et al.  Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. , 2005, Experimental cell research.

[38]  Sumithra J. Mandrekar,et al.  Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes , 2006 .

[39]  W. Henrich,et al.  Epidermal growth factor receptor changes during breast cancer metastasis. , 2006, Anticancer research.

[40]  J. Bartlett,et al.  The ERBB 4 / HER 4 Intracellular Domain 4 ICD Is a BH 3-Only Protein Promoting Apoptosis of Breast Cancer Cells , 2006 .

[41]  R. Nahta,et al.  HER2 therapy: Molecular mechanisms of trastuzumab resistance , 2006, Breast Cancer Research.

[42]  S. Keam,et al.  Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. , 2006, Drugs.

[43]  J. Bartlett,et al.  The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. , 2006, Cancer research.

[44]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[45]  P. Lønning,et al.  Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  G. Carruba,et al.  HER2/neu Expression in Relation to Clinicopathologic Features of Breast Cancer Patients , 2006, Annals of the New York Academy of Sciences.

[47]  Irene L Andrulis,et al.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.

[48]  A. Kurian,et al.  A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  G. Barosi,et al.  Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Caskey,et al.  The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. , 2007, Molecular endocrinology.

[51]  J. Jassem,et al.  Gene copy numbers of HER family in breast cancer , 2007, Journal of Cancer Research and Clinical Oncology.

[52]  A. Thor,et al.  Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells , 2007, International journal of cancer.

[53]  G Brockhoff,et al.  Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation , 2007, Cell proliferation.

[54]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[55]  L. Marrero,et al.  A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities , 2007, Oncogene.

[56]  John M.S. Bartlett,et al.  Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients , 2007, Clinical Cancer Research.